Dementia Biomarkers
Dementia Biomarkers - Related Videos
09:17
Using Retinal Imaging to Study Dementia
0 Views •
Cited by 19 •
2017
The retina shares prominent similarities with the brain and thus represents a unique window to study vasculature and neuronal structure in the brain non-invasively. This protocol describes a method to study dementia using retinal imaging techniques. This method can potentially aid in diagnosis and risk assessment of dementia.
06:23
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
0 Views •
Cited by 68 •
2016
This article describes the 4 Mountains Test (4MT), a hippocampus-dependent test of working allocentric spatial memory. The hippocampus is affected early in Alzheimer's disease (AD) and this article outlines the 4MT methodology and results of patient testing, which demonstrates the value of the 4MT in the diagnosis of pre-dementia AD.
01:30
Dementia
0 Views •
2025
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging. The progression of dementia is generally gradual.
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
0 Views •
Cited by 3 •
2016
We describe a high-throughput, multiplex, and targeted proteomic cerebrospinal fluid (CSF) assay developed with potential for clinical translation. The test can quantitate potential markers and risk factors for neurodegeneration, such as the apolipoprotein E variants (E2, E3 and E4), and measure their allelic expression.
01:22
Dementia l: Introduction
0 Views •
2026
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
FAQs
Their value comes from connecting clinical symptoms with biological changes rather than relying on memory complaints alone. Molecular signals and imaging findings can indicate whether cognitive decline is associated with particular disease processes, helping clinicians distinguish dementia syndromes from other causes of memory loss and make the overall evaluation more precise.
Amyloid-beta and phosphorylated tau are molecular signals that reflect disease-related processes detectable in cerebrospinal fluid or blood. When interpreted alongside clinical findings, they can help characterize the biological basis of cognitive decline. Their contribution is therefore complementary: they add molecular information that clinical assessment alone may not provide.
Fluid-based measures use molecular signals found in cerebrospinal fluid or blood, whereas imaging measures visualize changes within the brain. Imaging can show protein deposition, neuronal injury, or brain atrophy, while fluid measures provide biological signals from sampled body fluids. Using these categories together can provide complementary perspectives on disease-related change.
Memory loss does not by itself identify the underlying disease process. Biomarkers add evidence about molecular abnormalities, protein deposition, neuronal injury, or brain atrophy, helping separate dementia syndromes from other causes of cognitive symptoms. This distinction supports more accurate evaluation and can inform subsequent clinical decisions without replacing professional assessment.
A biomarker-informed evaluation combines clinical assessment with one or more biological measures, such as cerebrospinal fluid or blood signals and brain imaging findings. The results are interpreted together rather than in isolation. This integrated approach can relate observed cognitive decline to disease-related biology while preserving clinical assessment as an essential part of the process.
Biomarkers can help stratify patients, meaning organize them according to relevant biological characteristics or disease processes. In clinical research, this supports selection of participants and evaluation of treatment effects. The same information may also assist treatment selection in medicine, because biological findings can add context to the clinical picture when considering therapeutic approaches.
Because biomarkers reflect disease-related molecular or structural changes, they can contribute to prognostic assessment and to monitoring therapeutic response. In clinical research, repeated or comparative biomarker findings may help evaluate whether a treatment is affecting the targeted biological process. Their interpretation remains complementary to clinical assessment rather than serving as a standalone outcome.